Literature DB >> 8365945

Definitive postoperative irradiation of bile duct carcinoma with charged particles and/or photons.

R Schoenthaler1, J R Castro, F E Halberg, T L Phillips.   

Abstract

PURPOSE: To determine the rates of survival and local control in patients with bile duct adenocarcinomas treated with post-operative photons and/or charged particles. METHODS AND MATERIALS: A retrospective study was performed analyzing all patients with bile duct adenocarcinomas who received radiotherapy through the University of California San Francisco and at Lawrence Berkeley Laboratory between 1977 and 1987, a total of 62 patients. University of California San Francisco patients received photon therapy (median dose 5400 cGy), and Lawrence Berkeley Laboratory patients were treated with the charged particles helium and/or neon (median dose 6000 cGyE). Forty-eight patients were treated post-operatively with curative intent, 30 with photons and 18 with particles. Thirty-six patients in the study had gross residual disease; none had microscopically negative margins.
RESULTS: The overall two-year actuarial survival was 28%: 44% for particle-treated patients and 18% for patients treated with photons (p = .048). Median actuarial survival was 23 months in particle patients and 12 months in photon patients. Local control was also improved, though less significantly, in patients treated with particles (median disease-free survival 20 months vs. 4.5 months, p = .054). A univariate and multivariate analysis was performed and revealed that only extent of residual disease predicted local failure and overall survival; no other prognostic factors were identified.
CONCLUSION: Compared to conventional photon radiotherapy, treatment with post-operative charged particle irradiation at Lawrence Berkeley Laboratory appeared to offer a survival advantage in this non-randomized series. Additional investigation into protection of surrounding normal tissue with better dose localization through the use of charged particles is planned.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8365945     DOI: 10.1016/0360-3016(93)90423-s

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

1.  Multimodality therapy for locoregional extrahepatic cholangiocarcinoma: a population-based analysis.

Authors:  Clifton D Fuller; Samuel J Wang; Mehee Choi; Brian G Czito; John Cornell; Tania M Welzel; Katherine A McGlynn; Join Y Luh; Charles R Thomas
Journal:  Cancer       Date:  2009-11-15       Impact factor: 6.860

2.  Tamoxifen (TMX)/Fas induced growth inhibition of human cholangiocarcinoma (HCC) by gamma interferon (IFN-gamma).

Authors:  Selwyn M Vickers; Nirag C Jhala; Eun-Young Ahn; Jay M McDonald; George Pan; Kirby I Bland
Journal:  Ann Surg       Date:  2002-06       Impact factor: 12.969

3.  Carcinoma of the extrahepatic bile ducts. The University of California at San Francisco experience.

Authors:  R Schoenthaler; T L Phillips; J Castro; J T Efird; A Better; L W Way
Journal:  Ann Surg       Date:  1994-03       Impact factor: 12.969

Review 4.  Results of heavy ion radiotherapy.

Authors:  J R Castro
Journal:  Radiat Environ Biophys       Date:  1995-03       Impact factor: 1.925

5.  Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival.

Authors:  H A Pitt; A Nakeeb; R A Abrams; J Coleman; S Piantadosi; C J Yeo; K D Lillemore; J L Cameron
Journal:  Ann Surg       Date:  1995-06       Impact factor: 12.969

6.  Towards clinical evidence in particle therapy: ENLIGHT, PARTNER, ULICE and beyond.

Authors:  Stephanie E Combs; Manjit Djosanjh; Richad Pötter; Roberto Orrechia; Thomas Haberer; Marco Durante; Piero Fossati; Katia Parodi; Jacques Balosso; Ugo Amaldi; Michael Baumann; Jürgen Debus
Journal:  J Radiat Res       Date:  2013-07       Impact factor: 2.724

7.  Combined cytosine deaminase expression, 5-fluorocytosine exposure, and radiotherapy increases cytotoxicity to cholangiocarcinoma cells.

Authors:  L C Pederson; S M Vickers; D J Buchsbaum; S R Kancharla; M S Mayo; D T Curiel; M A Stackhouse
Journal:  J Gastrointest Surg       Date:  1998 May-Jun       Impact factor: 3.267

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.